Editor's
Choice
Main Category: Pain /
Anesthetics
Also Included In: Heart Disease; Pain / Anesthetics
Article Date: 21 Oct 2011 - 9:00 PDT
The case of Vioxx is
well documented and lesser issues such as gastrointestinal irritation from
Asprin are also well known. NSAIDS have been the subject of several European
reviews in relation to safety and side effects. The most recent completed in
2006, by the Agency's "Committee for Medicinal Products for Human
Use" (CHMP) decided that the overall benefit / risk balance remained
positive, but the possibility of a small increased risk of thrombotic events
such as heart attacks or stroke with
non-selective NSAIDs, could not be ruled out. Side effects will always exist
with any drug.
This was
particularly apparent when NSAIDs were used at high doses and for long-term
treatment. They concluded that future epidemiological studies would be needed
to obtain new data on pertinent safety aspects of NSAIDs and therefore the
Agency recommended in 2006 that the European Commission fund an independent
epidemiological study to further explore the risk of gastrointestinal and
cardiovascular toxicity of these medicines.
Since 2006, a number of new studies on the
cardiovascular safety of NSAIDs have been published. Recently, results from the
independent research project 'Safety Of non-Steroidal anti-inflammatory drugs'
(SOS) funded by the European Commission under the 7th framework program to
evaluate the safety of NSAIDs, have become available.
The CHMP will now review the results of this
meta-analysis thoroughly, together with any other available clinical data
(including data from clinical trials and epidemiological studies) and
post-marketing safety reports on non-selective NSAIDs, to clarify whether there
is any need to update the opinion issued in 2006.
by : http://www.medicalnewstoday.com/articles/236399.phpMain Category: Pain / Anesthetics
Also Included In: Heart Disease; Pain / Anesthetics
Article Date: 21 Oct 2011 - 9:00 PDT
The case of Vioxx is well documented and lesser issues such as gastrointestinal irritation from Asprin are also well known. NSAIDS have been the subject of several European reviews in relation to safety and side effects. The most recent completed in 2006, by the Agency's "Committee for Medicinal Products for Human Use" (CHMP) decided that the overall benefit / risk balance remained positive, but the possibility of a small increased risk of thrombotic events such as heart attacks or stroke with non-selective NSAIDs, could not be ruled out. Side effects will always exist with any drug.
This was particularly apparent when NSAIDs were used at high doses and for long-term treatment. They concluded that future epidemiological studies would be needed to obtain new data on pertinent safety aspects of NSAIDs and therefore the Agency recommended in 2006 that the European Commission fund an independent epidemiological study to further explore the risk of gastrointestinal and cardiovascular toxicity of these medicines.
Since 2006, a number of new studies on the cardiovascular safety of NSAIDs have been published. Recently, results from the independent research project 'Safety Of non-Steroidal anti-inflammatory drugs' (SOS) funded by the European Commission under the 7th framework program to evaluate the safety of NSAIDs, have become available.
The CHMP will now review the results of this meta-analysis thoroughly, together with any other available clinical data (including data from clinical trials and epidemiological studies) and post-marketing safety reports on non-selective NSAIDs, to clarify whether there is any need to update the opinion issued in 2006.
Did you check my new article fruit in the custard apple family crossword I desire you may adore it :)
ReplyDelete